Historique de carrière de Lynn Gallant
Anciens postes connus de Lynn Gallant
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| ENVERIC BIOSCIENCES, INC. | Directeur Technique/Scientifique/R&D | 22/02/2023 | 01/05/2023 |
BlueRock Therapeutics Canada ULC
 BlueRock Therapeutics Canada ULC BiotechnologyHealth Technology Bluerock Therapeutics engages in development of a pluripotent stem cell-derived myocardiocytes as regenerative cell therapies for restoring electrical and contractile function in patients with myocardial infarction or chronic heart failure. The company was founded by Gordon Keller and Lorenz Studer in 2016 and is headquartered in Toronto, Canada. | Directeur Technique/Scientifique/R&D | - | - |
Formation de Lynn Gallant
| University of New England | Undergraduate Degree |
Statistiques
Internationale
| Etats-Unis | 3 |
| Canada | 2 |
Opérationnelle
| Chief Tech/Sci/R&D Officer | 2 |
| Undergraduate Degree | 1 |
Sectorielle
| Health Technology | 3 |
| Consumer Services | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| ENVERIC BIOSCIENCES, INC. | Health Technology |
| Entreprise privées | 1 |
|---|---|
BlueRock Therapeutics Canada ULC
BlueRock Therapeutics Canada ULC BiotechnologyHealth Technology Bluerock Therapeutics engages in development of a pluripotent stem cell-derived myocardiocytes as regenerative cell therapies for restoring electrical and contractile function in patients with myocardial infarction or chronic heart failure. The company was founded by Gordon Keller and Lorenz Studer in 2016 and is headquartered in Toronto, Canada. | Health Technology |
- Bourse
- Insiders
- Lynn Gallant
- Expérience